Division of Pharmaceutical Technology, Defence Research Laboratory, Tezpur, 784001, India; Department of Pharmaceutical Sciences, Dibrugarh University, Dibrugarh, 786004, India.
Division of Pharmaceutical Technology, Defence Research Laboratory, Tezpur, 784001, India.
Phytomedicine. 2021 Aug;89:153610. doi: 10.1016/j.phymed.2021.153610. Epub 2021 May 25.
Obesity worsens airway hyperresponsiveness (AHR) in asthmatic subjects by up-regulating macrophage polarization that leads to excessive secretion of pro-inflammatory adipokines from white adipose tissue followed by generation of oxidative stress in the respiratory system. Treatment through conventional signaling pathways proved to be inadequate in obese asthmatics, so a therapeutical approach through a non-conventional pathway may prove to be effective.
This study aimed to investigate the efficacy of a FDA-approved food additive, β-caryophyllene (BCP) in obesity-associated AHR.
A repertoire of protein expression, cytokine and adiponectin estimation, oxidative stress assays, histopathology, and fluorescence immune-histochemistry were performed to assess the efficacy of BCP in C57BL/6 mice model of obesity-associated AHR. Additionally, human adipocyte was utilized to study the effect of BCP on macrophage polarization in Boyden chamber cell culture inserts.
Obesity-associated AHR is ameliorated by administration of BCP by inhibition of the macrophage polarization by activation of AMPKα, Nrf2/HO-1 and AdipoR1 and AdipoR2 signaling pathway, up-regulation of adiponectin, GLP-1, IFN-γ, SOD, catalase and down-regulation of NF-κB, leptin, IL-4, TNF, and IL-1β. Browning of eWAT by induction of thermogenesis and activation of melanocortin pathway also contributed to the amelioration of obesity-associated AHR. We conclude that BCP ameliorated the obesity-associated AHR via inhibition of macrophage polarization, activation of AMPKα, Nrf2/HO-1, and up-regulation of AdipoR1 and AdipoR2 expression and down-regulation of NFκB expression in lung of animal.
Being an FDA-approved food additive, BCP may prove to be a safe and potential agent against obesity-associated AHR.
肥胖通过上调巨噬细胞极化来加重哮喘患者的气道高反应性(AHR),从而导致白色脂肪组织中促炎脂肪因子的过度分泌,随后呼吸系统产生氧化应激。通过传统信号通路的治疗在肥胖型哮喘患者中被证明是不足的,因此通过非传统通路的治疗方法可能会被证明是有效的。
本研究旨在探讨 FDA 批准的食品添加剂 β-石竹烯(BCP)在肥胖相关 AHR 中的疗效。
采用蛋白质表达谱、细胞因子和脂联素测定、氧化应激测定、组织病理学和荧光免疫组织化学方法,评估 BCP 在肥胖相关 AHR 的 C57BL/6 小鼠模型中的疗效。此外,还利用人脂肪细胞研究了 BCP 对 Boyden 室细胞培养插入物中巨噬细胞极化的影响。
BCP 通过激活 AMPKα、Nrf2/HO-1 和 AdipoR1 和 AdipoR2 信号通路、上调脂联素、GLP-1、IFN-γ、SOD、过氧化氢酶和下调 NF-κB、瘦素、IL-4、TNF-α和 IL-1β来抑制巨噬细胞极化,从而改善肥胖相关 AHR。eWAT 的褐色化通过诱导产热和激活黑皮质素途径也有助于改善肥胖相关 AHR。我们得出结论,BCP 通过抑制巨噬细胞极化、激活 AMPKα、Nrf2/HO-1 和上调 AdipoR1 和 AdipoR2 表达以及下调 NFκB 表达来改善肥胖相关 AHR。
作为一种 FDA 批准的食品添加剂,BCP 可能被证明是一种安全且有潜力的针对肥胖相关 AHR 的药物。